BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Diagnosis
20 results:

  • 1. Characteristics of Molecular Genetic Mutations and Their Correlation with Prognosis in Adolescent and Adult Patients with Acute Lymphoblastic leukemia.
    Sun X; Liu X; Li Y; Shi X; Li Y; Tan R; Jiang Y; Sui X; Ge X; Xu H; Wang X; Fang X
    Oncology; 2024; 102(1):85-98. PubMed ID: 37437551
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
    Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
    Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Ethanolic extract of Coleus aromaticus leaves impedes the proliferation and instigates apoptotic cell death in liver cancer HepG2 cells through repressing JAK/STAT cascade.
    Shekh R; Tiwari RK; Ahmad A; Ahmad I; Alabdallah NM; Saeed M; Ansari IA; Mishra A; Ashfaque M; Bajpai P
    J Food Biochem; 2022 Oct; 46(10):e14368. PubMed ID: 35945689
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy.
    Sharma M; Fu MP; Lu HY; Sharma AA; Modi BP; Michalski C; Lin S; Dalmann J; Salman A; Del Bel KL; Waqas M; Terry J; Setiadi A; Lavoie PM; Wasserman WW; Mwenifumbo J; Kobor MS; Lee AF; Kuchenbauer F; Lehman A; Cheng S; Cooper A; Patel MS; Turvey SE
    Blood; 2022 Oct; 140(17):1858-1874. PubMed ID: 35789258
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
    Chifotides HT; Bose P; Verstovsek S
    J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Recent Advances in the Use of Molecular Analyses to Inform the diagnosis and Prognosis of Patients with Polycythaemia Vera.
    Stuckey R; Gómez-Casares MT
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34068690
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic leukemia.
    Tremblay D; Rippel N; Feld J; El Jamal SM; Mascarenhas J
    Oncologist; 2021 May; 26(5):406-421. PubMed ID: 33792103
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic leukemia and Atypical Chronic Myeloid leukemia.
    Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
    J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Study on Immunophenotypes and Gene of Acute Lymphoblastic leukemia].
    Zhao XF; Wang HY; Zhao X; Cheng HC; Li W; Liu SW; Qiu L; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):947-952. PubMed ID: 30111389
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Aggressive B-cell lymphomas in patients with myelofibrosis receiving jak1/2 inhibitor therapy.
    Porpaczy E; Tripolt S; Hoelbl-Kovacic A; Gisslinger B; Bago-Horvath Z; Casanova-Hevia E; Clappier E; Decker T; Fajmann S; Fux DA; Greiner G; Gueltekin S; Heller G; Herkner H; Hoermann G; Kiladjian JJ; Kolbe T; Kornauth C; Krauth MT; Kralovics R; Muellauer L; Mueller M; Prchal-Murphy M; Putz EM; Raffoux E; Schiefer AI; Schmetterer K; Schneckenleithner C; Simonitsch-Klupp I; Skrabs C; Sperr WR; Staber PB; Strobl B; Valent P; Jaeger U; Gisslinger H; Sexl V
    Blood; 2018 Aug; 132(7):694-706. PubMed ID: 29907599
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European leukemiaNet.
    Barbui T; Tefferi A; Vannucchi AM; Passamonti F; Silver RT; Hoffman R; Verstovsek S; Mesa R; Kiladjian JJ; Hehlmann R; Reiter A; Cervantes F; Harrison C; Mc Mullin MF; Hasselbalch HC; Koschmieder S; Marchetti M; Bacigalupo A; Finazzi G; Kroeger N; Griesshammer M; Birgegard G; Barosi G
    Leukemia; 2018 May; 32(5):1057-1069. PubMed ID: 29515238
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
    Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
    J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
    Delgado-Martin C; Meyer LK; Huang BJ; Shimano KA; Zinter MS; Nguyen JV; Smith GA; Taunton J; Winter SS; Roderick JR; Kelliher MA; Horton TM; Wood BL; Teachey DT; Hermiston ML
    Leukemia; 2017 Dec; 31(12):2568-2576. PubMed ID: 28484265
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.
    Vannucchi AM
    Haematologica; 2017 Jan; 102(1):18-29. PubMed ID: 27884974
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
    Koschmieder S; Mughal TI; Hasselbalch HC; Barosi G; Valent P; Kiladjian JJ; Jeryczynski G; Gisslinger H; Jutzi JS; Pahl HL; Hehlmann R; Maria Vannucchi A; Cervantes F; Silver RT; Barbui T
    Leukemia; 2016 May; 30(5):1018-24. PubMed ID: 26854026
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Contemporary approach to essential thrombocythemia and polycythemia vera.
    Aruch D; Mascarenhas J
    Curr Opin Hematol; 2016 Mar; 23(2):150-60. PubMed ID: 26717193
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The role of jak1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
    Keohane C; Mesa R; Harrison C
    Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Clinical and laboratory features of myelofibrosis and limitations of current therapies.
    Gregory SA; Mesa RA; Hoffman R; Shammo JM
    Clin Adv Hematol Oncol; 2011 Sep; 9(9 Suppl 22):1-16. PubMed ID: 22362131
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice.
    Mullighan CG
    Clin Cancer Res; 2011 Feb; 17(3):396-400. PubMed ID: 21149616
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Somatically acquired jak1 mutations in adult acute lymphoblastic leukemia.
    Flex E; Petrangeli V; Stella L; Chiaretti S; Hornakova T; Knoops L; Ariola C; Fodale V; Clappier E; Paoloni F; Martinelli S; Fragale A; Sanchez M; Tavolaro S; Messina M; Cazzaniga G; Camera A; Pizzolo G; Tornesello A; Vignetti M; Battistini A; Cavé H; Gelb BD; Renauld JC; Biondi A; Constantinescu SN; Foà R; Tartaglia M
    J Exp Med; 2008 Apr; 205(4):751-8. PubMed ID: 18362173
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.